Inactive

PRE-SOLICITATION NOTICE OF INTENT TO SOLE SOURCE Department of Veterans Affairs (VA) Network Contracting Office (NCO 21) intends to award a sole source, firm fixed price one-year contract to Boston Sc... PRE-SOLICITATION NOTICE OF INTENT TO SOLE SOURCE Department of Veterans Affairs (VA) Network Contracting Office (NCO 21) intends to award a sole source, firm fixed price one-year contract to Boston Scientific Corporation for Radioactive pharmaceutical Yttrium-90 (Y90) TheraSpheres to be delivered on an as needed bases. The procurement is on behalf of the Department of Veterans Affairs, Veterans Health Administration, Regional Procurement Office West (RPOW), Network Contracting Office (NCO) 21, on behalf of VAPAHCS. The specific items required are as follows: VA s Gray Market Counterfeit Items VAAR 852.212-72 is applicable. As a result, vendor shall be an OEM, authorized dealer, authorized distributor or authorized reseller for the item identified to be eligible for participation with this acquisition. Vendor must be able to provide the documentation that demonstrates such aforementioned authority. The solicitation for this action will be posted to beta.sam.gov and all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. After consideration, the Government will determine whether to proceed with the sole source acquisition. Please keep in mind that patient care and choice in the decision is the highest priority to the VA. The solicitation will be posted on or about August 17, 2021. Please respond to darralynn.freeman@va.gov no later than Tuesday, August 26, 2021 at 12:00 am Pacific time. With your response, please provide evidence showing compliance with the aforementioned Gray Market clauses. Failure to provide the required information may result in a determination that your company is not a viable source. (End of Notice)

Inactive

TheraSphere s Y-90 microspheres therapy is a minimally invasive outpatient procedure and patients usually go home hours after the procedure is completed. As of March 2021, TheraSphere Y-90 is the only... TheraSphere s Y-90 microspheres therapy is a minimally invasive outpatient procedure and patients usually go home hours after the procedure is completed. As of March 2021, TheraSphere Y-90 is the only recently fully FDA approved microsphere radiation therapy in the United States for the treatment of colorectal cancer that has spread to the liver. Theraspheres is a radiotherapy treatment for hepatocellular carcinoma (HCC) that consists of millions of microscopic, radioactive glass microspheres being infused into the arteries that feed liver tumors. These microspheres then embolize, lodging themselves in the liver's capillaries and bathing the malignancy in high levels of yttrium-90 radiation.

Inactive

TheraSphere s Y-90 microspheres therapy is a minimally invasive outpatient procedure and patients usually go home hours after the procedure is completed. As of March 2021, TheraSphere Y-90 is the only... TheraSphere s Y-90 microspheres therapy is a minimally invasive outpatient procedure and patients usually go home hours after the procedure is completed. As of March 2021, TheraSphere Y-90 is the only recently fully FDA approved microsphere radiation therapy in the United States for the treatment of colorectal cancer that has spread to the liver. Theraspheres is a radiotherapy treatment for hepatocellular carcinoma (HCC) that consists of millions of microscopic, radioactive glass microspheres being infused into the arteries that feed liver tumors. These microspheres then embolize, lodging themselves in the liver's capillaries and bathing the malignancy in high levels of yttrium-90 radiation.